Biotechnology M&A » By The Online Investor Staff, updated Sat., Apr. 20, 2:39 AM
Recent mergers and acquisitions in the Biotechnology M&A category.
| This Slide: #75 of 83 |
Slide #75. Gilead Sciences, Inc. — YM BioSciences Inc.
Acquirer:
Gilead Sciences, Inc. (GILD)
Acquiree:
YM BioSciences Inc. (YMI)
Details:
Gilead Sciences, Inc. and YM BioSciences Inc. announced that the companies have signed a definitive agreement under which Gilead will acquire YM for U.S.$2.95 per share in cash. The transaction has received the unanimous approval of YM's Board of Directors, and values YM at approximately U.S.$510 million, with YM reporting C$125.5 million in cash and cash equivalents as of September 30, 2012. Gilead plans to fund the acquisition with cash on hand. The transaction is expected to close in the first quarter of 2013.
Gilead Sciences is a biopharmaceutical company, focusing on medicines to prevent and treat diseases, including HIV, viral hepatitis and cancer. Co.'s products include: Biktarvy®, which is an oral formulation dosed once a day for the treatment of HIV-1 infection in certain patients; Veklury® (remdesivir), an injection for intravenous use, which is a nucleotide analog RNA polymerase inhibitor indicated for certain patients for the treatment of COVID-19 requiring hospitalization; and Epclusa®, which is an oral formulation of a once-daily single tablet regimen of sofosbuvir and velpatasvir for the treatment of chronic hepatitis C virus (HCV) infection in adults and certain pediatric patients.
Gilead Sciences SEC Filing Email Alerts Service
Open the GILD Page at The Online Investor »
Gilead Sciences is a biopharmaceutical company, focusing on medicines to prevent and treat diseases, including HIV, viral hepatitis and cancer. Co.'s products include: Biktarvy®, which is an oral formulation dosed once a day for the treatment of HIV-1 infection in certain patients; Veklury® (remdesivir), an injection for intravenous use, which is a nucleotide analog RNA polymerase inhibitor indicated for certain patients for the treatment of COVID-19 requiring hospitalization; and Epclusa®, which is an oral formulation of a once-daily single tablet regimen of sofosbuvir and velpatasvir for the treatment of chronic hepatitis C virus (HCV) infection in adults and certain pediatric patients.
Gilead Sciences SEC Filing Email Alerts Service
Open the YMI Page at The Online Investor »
|
||||||||||||||||||||||||
|
|||||||||
 Free Email Alerts:
Get SEC Filing Alerts Get Dividend Alerts 
|
